Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.

Publication Type:

Journal Article


Cancer, Volume 109, Issue 6, p.1011-8 (2007)


Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Cost-Benefit Analysis, Disease-Free Survival, Female, gene expression, Humans, Lymph Nodes, Monte Carlo Method, Neoplasm Recurrence, Local, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, Tamoxifen, Treatment Outcome


The prognostic accuracy for distant recurrence-free survival using a 21-gene reverse-transcriptase polymerase chain reaction (RT-PCR) assay underwent validation in 668 lymph node-negative, estrogen receptor-positive women with early-stage breast cancer receiving tamoxifen on National Surgical Adjuvant Breast Program (NSABP) B-14. The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14.